SCHEMBL7538965

SCHEMBL7538965

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C/C(=N\O)c4ccc(F)cc4)CC3)cc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.68
DRD3 P35462 1/20 0.66
HSD17B10 Q99714 3/20 0.63
ALDH1A1 P00352 6/20 0.62
HPGD P15428 4/20 0.62
HTT P42858 4/20 0.62
LMNA P02545 3/20 0.62
TSHR P16473 2/20 0.62
BRD4 O60885 1/20 0.62
CYP2J2 P51589 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MEN1 O00255 7/20 0.61
KMT2A Q03164 7/20 0.61
NPC1 O15118 1/20 0.61
MAPK1 P28482 1/20 0.59
USP2 O75604 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
PIK3CG P48736 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7538969 1.00 KDM4E (0.68) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7539630 0.94 KDM4E (0.68) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7539624 0.94 KDM4E (0.68) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7542047 0.93 DRD3 (0.64) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7542053 0.93 DRD3 (0.64) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7541377 0.92 TDP1 (0.70) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7541368 0.92 TDP1 (0.70) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7538886 0.90 KDM4E (0.71) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7544304 0.87 DRD3 (0.72) KDM4EDRD3HSD17B10ALDH1A1HPGD
SCHEMBL7544309 0.87 DRD3 (0.72) KDM4EDRD3HSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions PHARMACEUTICAL INDUSTRY TECHNOLOGY 2002-05-23 US claimed
US-6492373-B2 FOR TREATMENT OF BACTERIAL INFECTIONS AND/OR RENAL CANCER DISEASES PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2002-12-10 US disclosed
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions PHARMACEUTICAL INDUSTRY TECHNOLOGY 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061895-A1 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions ATP6V1B1, GLS, RCC2 KDM4E 1113/4885DRD3 4072/4885HSD17B10 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.